Company* |
Company* (Country; Symbol) |
Type/ |
Terms/ |
| | |||
454 Life Sciences (subsidiary of CuraGen Corp.; CRGN) |
Pyrosequencing AB (Sweden; SSE: PYRO) |
Exclusive licensing agreement giving 454 use of sequencing by synthesis and pyrophosphate based-sequencing for whole-genome applications from Pyrosequencing |
The license gives 454 the exclusive right to use the technology in whole-genome analysis, while Pyrosequencing retains rights to its pyrophosphate-based sequencing technology for all applications not related to whole-genome activities; Pyrosequencing will receive a minimum of $4.5M in up-front payments and minimal royalties (8/19) |
4SC AG* |
Switch Biotech AG* (Germany) |
Collaboration under which 4SC will screen small molecules against a Switch psoriasis target |
4SC is getting an undisclosed up-front fee as well as potential milestone payments and royalties (10/13) |
Access Pharmaceuticals Inc. (AMEX:AKC) |
Celltech Group plc (UK; LSE:CCH) |
Collaboration to develop oral drug delivery options for Celltech's monoclonal antibodies and antibody fragments using Access's vitamin B-12 oral drug delivery technology |
Celltech was granted rights to license the Access technology for a defined number of antigens (9/11) |
Agencourt Bioscience Corp.* |
Ambion Inc.* |
Partnership that focuses on RNA-based research and molecular diagnostic products |
Ambion will distribute Agencourt's AMPure as a component in its MessageAmp RNA amplification kit (9/16) |
Affymetrix |
Cellular Genomics Inc.* |
Research collaboration under which CGI will use its ASKA technology with Affymetrix's GeneChip technology for kinase drug discovery |
The deal also includes demonstrating the utility of the chips in cell-based assay development and lead discovery (10/9) |
Affymetrix |
Paradigm Genetics Inc. (PDGM) |
Paradigm will provide microarray processing services using Affymetrix's GeneChip technology |
Paradigm also licensed rights to use Affymetrix technologies in internal research programs; financial terms were not disclosed (10/20) |
Affymetrix |
Spectral Genomics Inc.* |
Spectral gained a worldwide license to certain patents to manufacture and sell spotted DNA arrays for the research market |
The license provides additional intellectual property rights for Spectral products and services; financial terms were not disclosed (10/20) |
Agilent |
Agendia BV* |
Agreement in which Agendia selected Agilent's custom microarrays as the platform for its cancer research |
The aim is to validate the technology for potential clinical and diagnostic applications (8/21) |
AlgoRx |
BresaGen Ltd. (Australia; ASX:BGN) |
Agreement in which BresaGen acquired the Xeriject drug delivery platform from AlgoRx |
AlgoRx retains rights to the technology for pain applications (9/12) |
Archemix Corp.* |
Aptamera Inc.* |
License and product development agreement for Aptamera's anticancer drug ARGO100 |
Aptamera gains a nonexclusive right to use Archemix's intellectual property for therapeutic development purposes (8/22) |
Arius Research |
Protein Design Labs Inc. (PDLI) |
Three-year agreement to discover and develop antibodies for cancer |
Arius gets an up-front fee to discover antibodies; PDL will perform validation studies and has an option to license them for further development; Arius would get license fees, milestones and royalties on products developed; specific financial terms were not disclosed (10/2) |
Arizeke |
Copernicus Therapeutics Inc.* |
Exclusive rights agreement for Arizeke to gain access to patents related to the development of targeted smart drugs absorbed systemically following oral or aerosol delivery |
Financial terms were not disclosed (9/15) |
Arpida Ltd.* |
Polyphor Ltd.* (Switzerland) |
Collaboration to discover antimicrobial compounds that combines Arpida's platform with Polyphor's medicinal chemistry |
The companies will jointly take lead molecules through preclinical development (10/15) |
Bio-Rad |
Cell Signaling Technology Inc.* |
Research, supply and co- marketing agreement in which Bio-Rad will develop multiplex bead-based assays for its BioPlex suspension array system using antibodies developed and validated by CST |
The resulting assays will enable the simultaneous assessment of multiple molecules that play a role in cellular signaling; a focus of the collaboration is Bio-Rad's development of multiplex assays that detect protein phosphorylation (9/2) |
Biovitrum AB* |
Amgen Inc. (AMGN) |
Agreement centered on Biovitrum's small-molecule inhibitors of 11 beta-hydroxy-steroid dehydrogenase-1 and including BVT.3498 (9/8) |
Amgen will pay $86.5M up front, will fund a three-year Biovitrum research program on the inhibitors, and will fund and conduct all development and commercialization in the licensed territories that include North America, South America, the European Union, Australia and New Zealand |
Cambrex Corp. (NYSE:CBM) |
Analytical BioChemistry Laboratories Inc.* |
Agreement to provide Cambrex's pharmaceutical customers with extended services through access to ABC's development and analytical offerings |
Financial terms were not disclosed (9/4) |
Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) |
Enzon Pharmaceuticals Inc. (ENZN) and Micromet AG* (Germany) |
Licensing agreement in which CAT gained access to a single-chain antibody patent estate jointly owned by Micromet and Enzon in exchange for access to CAT's antibody phage display intellectual property |
The trio received rights to develop antibody-based therapeutic and diagnostic products based on research that taps one another's technology; each party could receive royalties from resulting products developed with the licensed technology (9/3) |
Cangene Corp. |
Acambis plc (UK; LSE:ACM) |
Research and development agreement to develop and manufacture a hyperimmune globulin for treating and preventing infection by West Nile virus |
The companies will share development and funding for the project; Acambis will provide its ChimeriVax West Nile vaccine, product assay technology and testing for efficacy of the product; Cangene will collect plasma and develop and manufacture the product (9/3) |
Cellectricon |
Axon Instruments Inc.* |
Axon gained license to Cellectricon's electroporation technology |
Axon will incorporate the technology into its Axoporator line of products; financial terms were not disclosed (10/8) |
ChemCodes Inc.* |
VM Discovery Inc.* |
Alliance to further ChemCodes' internal drug discovery programs |
The partners will use VM's computational-driven drug discovery predictive models for scaffold hopping, virtual design and screening libraries and filtering to find drug-like leads and clinical candidates (8/18) |
Chemical |
Mpex Pharmaceuticals Inc.* |
Agreement under which CDL will provide a library of 100,000 compounds to aid Mpex's discovery of antibacterial agents |
CDL also will provide various chemistry services; financial terms were not disclosed (9/29) |
Chemical |
Biogen Inc. (BGEN) |
Vitrual screening agreement giving Biogen access to CDL compounds for drug discovery |
Financial terms were not disclosed (10/15) |
Chimerix Inc.* |
Gilead Sciences Inc. (GILD) |
Licensing agreement for rights to develop oral derivatives of Gilead's antiviral compound, Vistide (cidofovir), for smallpox infection |
Chimerix will continue the development of a modified derivative of cidofovir, CMX-001; Chimerix has rights to sell CMX-001 to governments worldwide; the license also includes the rights to develop and sell it for treatments of related viral infections; Chimerix would pay Gilead royalties (9/12) |
Chromos Molecular Systems Inc. (Canada; TSE:CHR) |
Xencor Inc.* |
Nonexclusive research license agreement to develop cell lines that express Xencor's monocloncal antibodies and other recombinant proteins |
Chromos receives an undisclosed up-front fee and annual maintenance fees; Xencor has an option to negotiate a license for manufacturing its clinical products (9/23) |
Corixa |
Apovia AG* (Germany) |
Research, development and commercialization agreement for Corixa's synthetic adjuvant RC-529 |
The multiyear agreement grants Apovia commercial rights to RC-529 for use in an undisclosed therapeutic vaccine; the companies will equally share research, development and commercialization costs, as well as any potential product revenue (8/17) |
Corixa |
DakoCytomation A/S* (Denmark) |
Agreement in which DakoCytomation gained exclusive worldwide rights to two antibodies for prostate cancer diagnostics and monitoring |
DakoCytomation will have the exclusive right to develop and commercialize immunohistochemistry diagnostics and the right to develop therapeutic drug-monitoring products related to P504S, a tumor-specific marker, and PS01S, specific for prostate tissue (9/3) |
Crucell NV (the Netherlands; CRXL) |
Gene Medicine Japan Inc.* (Japan) |
GMJ licensed Crucell's PER.C6 cell line to provide manufacturing services for biotechnology products |
Crucell will receive undisclosed up-front and annual payments, as well double-digit royalties on manufacturing sales (10/14) |
Crucell NV (theNetherlands; CRXL) |
Novavax Inc. (NVAX) |
License agreement to offer vaccine manufacturing services on Crucell's PER.C6 technology; Novavax also will use the technology on two targeted vaccines |
Crucell will receive up-front and annual payments, as well as royalties on contract manufacturing sales by Novavax (9/25) |
Cubist Pharmaceuticals Inc. (CBST) |
Chiron Corp. (CHIR) |
Chiron licensed rights to the antibiotic Cubicin in Europe, Australia, New Zealand, India and certain other countries |
Chiron will pay up to $50M, including $18M up front and $10M of which will go toward buying equity at a 50 percent premium; Cubist also can earn milestones and royalties on sales (10/3) |
CytRx |
SynthRx Inc.* |
CytRx licensed co-polymer technologies, including Flocor, and related anti-infective products to SynthRx |
CytRx is getting an undisclosed up-front payment and a 19.9% stake in SynthRx; it also could earn milestone and royalty payments (10/23) |
DanioLabs |
Oxagen Ltd.* (UK) |
Collaboration for DanioLabs to use its inflammatory bowel disease model to screen compounds from a G protein-coupled receptor program belonging to Oxagen |
The compounds resulted from Oxagen's work to screen against inflammatory bowel disease-associated target receptors identified in its GPCR program (9/22) |
DiaDexus Inc.* |
Human Genome Sciences Inc. (HGSI) |
License agreement under which HGSI gained worldwide rights to diagnostic immuno-histochemical tests based on the TrailReceptor-1 and -2 proteins |
DiaDexus retains rights to diagnostics in other formats; DiaDexus gets an undisclosed up-front payment and potential milestone and royalty payments (10/16) |
Diversa |
Medarex Inc. (MEDX) |
Co-sponsored partnership to develop antibodies with enhanced functionality |
Diversa and Medarex are combining their work in directed evolution and antibody biology, respectively, in the joint research effort (10/16) |
Dyax |
URRMA Biopharma Inc.* (Canada) |
Agreement for discovery and development of fully human monoclonal antibodies to the R7V antigen on HIV |
The companies will jointly develop products and commercialize them; there is an option to develop URRMA's existing R7V antibody, under which Dyax would pay a license fee (10/23) |
Dyax |
MedImmune Inc. (MEDI) |
Nonexclusive license to Dyax's antibody phage display libraries |
Dyax gets undisclosed up-front and annual maintenance fees as well as potential milestones and royalties from MedImmune's use of libraries (9/30) |
Endovasc Inc. (OTC BB:EVSC) |
TissueGen Inc.* |
Joint venture agreement to create Endovasc-TissueGen Research Sponsors LLC to support development of a bioresorbable drug-eluting cardiovascular stent |
Endovasc licensed its time-released prostaglandin E1 drug to the joint venture and purchased a $150,000 convertible promissory note to fund a prototype development (8/21) |
EntreMed Inc. |
Oxford BioMedica plc (UK; LSE:OXB) |
Agreement granting exclusive worldwide rights to Oxford to develop the localized delivery of two gene targets for vision loss |
Oxford gained rights to use EntreMed's endostatin and angiostatin genes in its therapeutic RetinoStat program for age-related macular degeneration and diabetic retinopathy; EntreMed received an initial cash payment and common stock in Oxford, and may collect up to $10M based on regulatory and clinical milestones (9/9) |
Epoch Biosciences |
Millennium Pharmaceuticals Inc. (MLNM) |
License agreement to Epoch's MGB Eclipse Probe Systems for gene expression analysis |
Epoch will develop and supply the arrays for Millennium gene targets; financial terms were not disclosed (10/14) |
Evotec OAI AG (Germany; FSE: EVT) |
DeveloGen AG* (Germany) |
Joint drug discovery and development partnership in the field of obesity and diabetes |
The partners plan to share risks and rewards equally (9/10) |
Evotec OAI |
Biofrontera Pharmaceuticals Holding AG* (Germany) |
Co-marketing deal to offer natural compounds for drug discovery services |
Evotec will incoporate Bionfrontera compounds into its screening services; Biofrontera will not enter this type of deal with other companies but can collaborate on its own; terms were not disclosed (10/14) |
F2G Ltd.* (UK) |
Asinex Ltd.* (Russia) |
Collaboration in which F2G will screen against a variety of targets and whole-cell assays using compounds belonging to Asinex |
Asinex will allow F2G to develop the compounds as antifungal drugs (9/9) |
F2G Ltd.* (UK) |
InterBioscreen* (Russia) |
Agreement in which F2G will work to find new sys- temic antifungal drugs by screening for antifungal activity against its HTS and whole-cell assays to further develop promising leads |
The agreement includes an option to further collaborate on developing specific areas of interest (9/9) |
Genencor International Inc. (GCOR) |
BioTrove Inc.* |
BioTrove purchased intellectual property covering through hole array technology |
Financial terms were not disclosed (9/29) |
Generex Biotechnology Corp. (Canada; GNBT) |
Transgene SA (France; TRGNY) |
Collaboration under which Generex's Ii suppresor gene will be tested in Transgene's cancer immunotherapy products |
The work invovles Generex's Antigen Express subsidiary; terms were not disclosed (10/15) |
Genetronics Biomedical Corp. (AMEX:GEB) |
Vical Inc. (VICL) |
Agremeent under which Vical gained the option to use Genetronics' in vivo electroporation delivery technology with its vaccine and DNA technology for undisclosed therapeutic targets |
Companies will decide on a license agreement after research phase; financial terms were not disclosed (10/20) |
Genzyme Genetics |
Laboratory Corp. of American Holdings (NYSE:LH) and Baylor College of Medicine |
Licensing agreements that provide access to Genzyme's cancer diagnostic patent rights related to the APC and p53 genes |
Laboratory Corp. and Baylor College were granted nonexclusive diagnostic rights for use in diagnostic testing services that detect increased risk for certain colon cancers; Genzyme Genetics receives an up-front licensing fee and would earn royalties on each diagnostic test performed (9/5) |
Graffinity Pharmaceuticals AG* (Germany) |
Genentech Inc. (NYSE:DNA) |
Research and development collaboration to identify and develop small-molecule therapeutics |
Genentech will provide a number of drug targets to Graffinity, which will deliver lead structures for the targets after using its RAISE technology (9/18) |
High |
ProSkelia SA* (France) |
ProSkelia purchased HTG's ArrayPlate technology for use in drug discovery |
Financial terms were not disclosed (10/21) |
Hybridon Inc. (OTC BB:HYBN) |
The Immune Response Corp. (IMNR) |
Immune Response licensed Amplivax for use as an adjuvant in an HIV vaccine |
The vaccine incorporates the immunomodulatory oligonucleotide adjuvant with Immune Response's Remune; financial terms were not disclosed (10/9) |
Iconix |
Millennium Pharmaceuticals Inc. (MLNM) |
Agreement under which Iconix will provide chemogenomic technologies for Millennium's drug discovery programs |
Financial terms were not disclosed (10/21) |
IDEC Pharmaceuticals Corp. (IDPH) |
Quorex Pharmaceuticals Inc.* |
Collaboration that will use Quorex's Protein Vision bioin- formatics platform to identify genes encoding proteins for use as therapeutic targets to treat cancers or inflammatory disorders |
Financial terms include undisclosed up-front and research payments (9/3) |
Idun |
Biogen Inc. (BGEN) |
Sublicensing agreement granting Biogen access to an apoptosis gene technology on a nonexclusive basis |
Biogen will use the technology to enhance the productivity of its clinical and commercial pharmaceutical product manufacturing processes and will get access to Idun's Bcl-2 family genes (8/21) |
International Medical Innovations Inc. (Canada; TSE:IMI) |
AtheroGenics Inc. (AGIX) |
Collaboration in which IMI's cardiovascular risk assess- ment test, Cholesterol 1,2,3, will be added to AtheroGenics' international ARISE trial |
ARISE is a Phase III study designed to evaluate the impact of AGI-1067 to treat atherosclerosis (8/28) |
Immune Network Ltd. (Canada; OTC BB: IMMFF) |
Advectus Life Sciences Inc. (Canada; VSE:AVX) |
Agreement in which Advectus acquired an option for an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease, based on compositions that penetrate the blood-brain barrier with existing drugs |
Advectus will pay option fees over a period of six months; terms include an up-front licensing fee of C$100,000 (US$73,000), a milestone payment of C$100,000 upon first clinical trial commencement, and C$5M in cash or equity upon first marketing approval (9/5) |
Innate |
SIGA Technologies Inc. (SIGA) |
Collaboration using Innate's platform to discover anti- infective compounds and SIGA's expertise to develop small molecules to neutralize potential biowarfare agents |
The companies plan to develop an anti- infective to prevent or treat plague (9/26) |
InNexus Biotechnology Inc. (Canada; VSE: IXS) |
Corixa Corp. (CRXA) |
Antibody agreement in which the companies will develop lead antibody candidates combining InNexus' Super- Antibody Technology with up to four antibodies from Corixa's therapeutic antibody development program |
The collaboration initially will focus on enhancing the antitumor activity of selected antibody leads that are in development; Corixa would have the right to license the technology from InNexus in exchange for up-front, milestone and royalty payments (9/11) |
Inpharmatica |
British Biotech plc (now Vernalis plc, UK; BBIOF) |
Two-year agreement for the provision of ADME services in connection with drug discovery activities |
Inpharmatica's ADME team will provide assays, analysis and interpretation of ADME data for a number of different project teams at British Biotech (9/4) |
Inproteo* (partnership bet- ween Indiana and Purdue universities and Eli Lilly and Co.) |
Biogen Inc. (BGEN) |
Biogen gained license to "Smith" patent covering His Tag fusion protein-purification technology |
The license covers all uses of the technology for the life of the patent; financial terms were not disclosed (10/7) |
Invitrogen |
Agencourt Bioscience Corp.* |
Partnership designed to result in wider distribution of Invitrogen's Serial Analysis of Gene Expression technology |
Invitrogen's kits will include discounted services by Agencourt; financial terms were not disclosed (9/29) |
Lorus Therapeutics Inc.* |
Cyclacel Ltd.* (UK) |
Cyclacel gained worldwide rights to Lorus's small-molecule cancer compound (CYC381; NC381) and related compounds |
Lorus receives an up-front payment of $400,000 and potential milestones of $11.6M for each compound developed; it also would get sales royalties (9/24) |
Nanogen Inc. (NGEN) |
Prodesse Inc.* |
Agreement to develop automated microarray-based products to detect a number of infectious disease agents, including influenza, pneumonia, adenovirus, herpes, West Nile virus and severe acute respiratory syndrome |
The companies will integrate Prodesse's multiplex amplification technology with Nanogen's automated NanoChip platform and jointly develop and market gene-based testing products to health care providers and clinical reference labs (9/10) |
NexGen Bacterium Inc.* |
BioBalance Corp. (subsidiary of New York Health Care; BBAL) |
Agreement in which Bio- Balance acquired a platform technology of biotherapeutic agents from NexGen |
The acquisition includes strains of Bacillus across all gastrointestinal indications; financial terms include a one-time payment of $250,000 and 1M shares of restricted stock in New York Health Care (8/21) |
Nuvelo Inc. (NUVO) |
Sequenom Inc. (SQNM) |
Agreement in which Nuvelo assigned its entire chemical cleavage patent estate to Sequenom |
Nuvelo will receive an undisclosed licensing payment and potential royalties for any revenues from sublicensing of the restriction enzyme patents (9/17) |
Odyssey Thera Inc.* |
Dharmacon Inc.* |
Research collaboration to study the effects of siRNA-induced gene silencing on cellular signaling pathways |
The collaboration will combine Dharmacon's SMART technologies for gene silen- cing and Odyssey Thera's Protein-fragment Complementation Assay process in the quantification and analysis of signaling events within the context of living human cells (9/15) |
OncoMethylome Sciences SA* (Belgium) |
Serologicals Corp. (SERO) |
Agreement under which Serologicals gained rights to methylation-specific PCR technology |
Serologicals gains all rights to serve the research market and OMS has rights to the clinical development market and in vitro diagnostics; Serologicals received an undisclosed payment (10/7) |
OriGene Technologies Inc.* |
Tanox Inc. (TNOX) |
Research collaboration for functional study of human cDNA clones encoding membrane-bound proteins |
Tanox gets rights for therapeutic applications; OriGene retains rights to research and diagnostic reagent development (10/8) |
Pharmacopeia Inc. (PCOP) |
Neurocrine Biosciences Inc. (NBIX) |
Research collaboration to identify promising small-molecule compounds from Pharmacopeia's library |
Pharmacopeia will receive research funding to identify leads against Neurocrine targets, and could get milestone and royalty payments from the deal (10/20) |
Pharmasset Ltd.* |
Incyte Corp. (INCY) |
Agreement in which Incyte gained exclusive development, manufacturing and marketing rights to Reverset in the U.S., Europe and other unnamed markets |
Incyte will pay Pharmasset an undisclosed up-front payment, milestone payments and royalties on net sales; Pharmasset retains marketing and commercialization rights in South America, Mexico, Africa, the Middle East, Korea and China (9/8) |
Pharmastem Therapeutics Inc.* (formerly Biocyte Corp.) |
StemCyte Inc.* |
StemCyte obtained a license to a patent portfolio in the areas of blood and placenta preservation |
Financial terms were not disclosed (9/23) |
Predix Pharmaceuticals Holdings Inc.* |
BioAnalytics Group LLC* |
BioAnalytics licensed software and simulation technology to accelerate development of model-based assays |
BioAnalytics also gained rights to patents in the area; financial terms were not disclosed (10/7) |
Receptor BioLogix Inc.* |
Incyte Corp. (INCY) |
Licensing agreement for selected applications of Receptor's technology to Incyte |
Incyte will use the license for its small- molecule cancer program and will make an undisclosed up-front investment along with future milestone payments and royalties in return for access to technology outside of Receptor's core business involving Intron Fusion Proteins (9/22) |
Replidyne Inc.* |
Array BioPharma Inc. (ARRY) |
Collaboration in which Replidyne will work to create small-molecule therapeutics targeting bacterial infections |
Replidyne would be responsible for all preclinical and clinical development and commercialization of compounds disco- ered during the collaboration, and will fund lead optimization at Array (9/18) |
Replidyne Inc.* |
Sequoia Sciences Inc.* |
Agreement in which Replidyne will gain access to libraries of plant-isolated compounds that belong to Sequoia |
Replidyne will be responsible for high- throughput screening of the libraries, lead optimization, development and commercialization, and will work with Sequoia on compound identification (9/18) |
Structural GenomiX Inc.* |
OSI Pharmaceuticals Inc. (OSIP) |
Agreement in which Structural GenomiX will set about solving the 3-D structure of multiple OSI drug targets with its large-scale protein structure determination methods |
OSI is providing an undisclosed amount of up-front cash, plus committed research funding and milestone payments (9/3) |
Thuris Corp.* |
Degussa Food Ingredients (unit of Degussa AG; Germany) |
Collaboration to determine sites of action of certain brain-active compounds |
Thuris will test Degussa compounds in behavioral assays and its BrainPrint (8/18) |
Transkaryotic Therapies Inc. (TKTX) |
Genyme Corp. (GENZ) |
Collaboration under which Genzyme will develop and commercialize iduronate-2 sulfatase for Hunter syndrome in Asia-Pacific areas |
TKT keep rights elsewhere; Genzyme is paying $3M up front and up to $8M in milestones; TKT would manufacture the product in Asia and receive one-third of sales there (10/8) |
Trillium Therapeutics Inc.* (Canada) |
Medarex Inc. (MEDX) |
Collaboration to develop fully human antibody therapeutics |
Companies will shares costs and responsibilities of commercialization, and would share resulting revenues (10/2) |
Tripos Inc. (TRPS) program targeting a nicotinic acetylcholine receptor |
Critical Therapeutics Inc.* |
Agreement under which Tripos will identify and optimize small-molecule agonists for CTI's |
Tripos will receive research payments and would get additional payments if milestones are achieved (10/22) |
X-Cell Medical Inc.* |
Biosensors International* (subsidiary of Sun Biomedical Ltd.; Singapore) |
Agreement to create a joint venture to develop drug-eluting stent technologies with anti-restenotic candidates |
The venture will combine Biosensors' core focus in drug and polymer synthesis, stent designs and catheter delivery systems with XCell's anti-restenosis drug discovery programs, compounds and scientific team (9/16) |
| | |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | |||
